FUNDACION PARA LA INVESTIGACION DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA

Their core work

HULAFE is the research foundation of La Fe University Hospital in Valencia, one of Spain's largest public hospitals. They specialize in translational clinical research — bridging laboratory science and patient care — with deep strength in cancer diagnostics, medical imaging AI, hematological malignancies, and toxicology risk assessment. Their work focuses on turning clinical data and imaging into predictive tools for personalized medicine, particularly in oncology. They also contribute clinical expertise to projects in palliative care, organ transplantation, and maternal-fetal health.

What they specialise in

How they've shifted over time

In their early H2020 period (2015–2018), HULAFE focused on foundational clinical research: computational toxicology (EU-ToxRisk), hematological malignancies (HARMONY, MDS-RIGHT), and cystic fibrosis self-management (MyCyFAPP). From 2018 onward, their work shifted decisively toward AI-powered medical imaging and cancer precision diagnostics, coordinating both PRIMAGE and CHAIMELEON — projects that build imaging biomarker repositories and regulatory-compliant AI tools for oncology. This evolution reflects a hospital research foundation moving from contributing clinical data to leading the development of computational diagnostic infrastructure.

HULAFE is positioning itself as a European hub for regulatory-compliant AI imaging tools in oncology, combining clinical data access with computational modelling expertise — expect continued growth in medical AI and precision diagnostics.

How they like to work

HULAFE primarily operates as an active clinical partner (18 of 22 projects), contributing patient data, clinical validation, and hospital infrastructure to large consortia. When they coordinate (4 projects), they lead clinically-driven digital health initiatives — notably PRIMAGE and CHAIMELEON, both high-budget cancer imaging projects. With 321 unique partners across 30 countries, they are a well-connected hub rather than a repeat-partner organization, making them an accessible and experienced consortium member for new collaborations.

HULAFE has collaborated with 321 distinct partners across 30 countries, giving them one of the broader networks among Spanish hospital research foundations. Their reach spans all major EU research nations with no narrow geographic clustering.

What sets them apart

HULAFE combines something rare: direct access to a major hospital's clinical data and patient populations with growing computational and AI capability. Unlike pure tech partners who build algorithms without clinical grounding, or pure hospitals that contribute data passively, HULAFE actively coordinates AI imaging projects and shapes their regulatory compliance frameworks. For consortium builders, they offer a single partner that bridges clinical reality and digital innovation in oncology.

Highlights from their portfolio

• CHAIMELEON
  Coordinated with EUR 1.1M budget — building a regulatory-compliant repository of AI tools for cancer management across lung, breast, colorectal, and prostate cancer.
• PRIMAGE
  Coordinated with EUR 1.2M — developed predictive in-silico multiscale analytics for childhood cancers (neuroblastoma, DIPG), combining imaging biomarkers with computational modelling.
• HARMONY
  EUR 1M participation in Europe's largest big data platform for hematological malignancies, covering leukemia, lymphoma, and myelodysplastic syndromes.